Tango Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Tango Therapeutics

02/05/2025 15:16

Tango Therapeutics Inc TNGX.OQ TNGX.O is expected to show a rise in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

The Boston Massachusetts-based  company is expected to report a 3.4% increase in revenue to $6.694 million from $6.47 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Tango Therapeutics Inc is for a loss of 35 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Tango Therapeutics Inc is $10.00​, above​ its last closing price of $1.41. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.33
-0.34
-0.35
Missed
-3.3
Sep. 30 2024
-0.35
-0.37
-0.27
Beat
26.5
Jun. 30 2024
-0.35
-0.34
-0.24
Beat
30.4​
Mar. 31 2024
-0.31
-0.31
-0.35
Missed
-11.9
​​Dec. 31 2023
-0.30
-0.28
-0.32
Missed
-15.2
Sep. 30 2023
-0.34
-0.34
-0.23
Beat
33.3​
Jun. 30 2023
-0.31
-0.34
-0.23
Beat
31.5
Mar. 31 2023
-0.35
-0.35
-0.32
Beat
8.9

This summary was machine generated May 2 at 14:16 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)